Search
Back

Abiraterone Acetate

CAS 154229-18-2
Abiraterone Acetate

General Information

Abiraterone Acetate is used for treatment of metastatic castrate-resistant prostate cancer. It is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.


About the API

Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Abiraterone Acetate

March 9, 2016
New EU DMF dated 02/2016 is available.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.